Large-Scale Registry Study Links GLP-1 Medications to 42% Reduction in Psychiatric Hospitalizations and Sickness Absence

A massive study from the University of Eastern Finland finds GLP-1 medications like semaglutide significantly reduce hospital care for depression and anxiety.

By: AXL Media

Published: Mar 19, 2026, 7:07 AM EDT

Source: Information for this report was sourced from University of Eastern Finland

Investigating the Metabolic-Mental Health Nexus

The intersection of metabolic diseases and mental health has long been a focal point for clinical research, as individuals with diabetes and obesity face a significantly higher risk of developing psychiatric symptoms. Conversely, those with mental health disorders are more prone to metabolic complications. A new registry-based study led by the University of Eastern Finland, in collaboration with the Karolinska Institutet and Griffith University, has provided compelling evidence that GLP-1 medications—originally designed for glycemic control and weight loss—may offer profound benefits for psychological well-being and behavioral health.

Significant Risk Reductions in Depression and Anxiety

By tracking nearly 100,000 participants through Swedish national registers between 2009 and 2022, researchers identified a stark contrast in psychiatric outcomes during periods of GLP-1 use. The study found that semaglutide use was associated with a 42% reduction in sickness absence and hospital care due to psychiatric reasons compared to non-use periods. Specifically, the risk for depression-related medical intervention was 44% lower, while anxiety disorders saw a 38% decrease. These findings suggest that the medication's impact extends far beyond weight management, potentially stabilizing mood through various physiological channels.

Impact on Substance Use and Suicidal Behavior

One of the most striking findings of the research was the medication's association with a 47% lower risk of hospital care related to substance use disorders. This aligns with previous observations that GLP-1 receptor agonists may temper cravings and addictive behaviors. Furthermore, the use of these medications was linked to a reduced risk of suicidal behavior, a critical metric in psychiatric safety. Researchers noted that the reduction in alcohol-related issues often has a positive "downstream" effect on overall mood, which likely contributed to the broad improvements seen across the study population.